Cancer Therapy and the p53-MDM2 Autoregulatory Feedback Loop
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 4685
Special Issue Editors
Interests: p53; MDM2; tumour suppressor; oncogene; targeted therapy
Special Issue Information
Dear Colleagues,
Mutations in the TP53 gene are by far the most common genetic alterations in cancer. Loss of p53 function is frequently linked to reduced therapeutic responses, resulting in poor patient outcomes. Almost 100,000 publications have investigated p53, which is testament to the immense importance the scientific and medical research communities place on understanding this critical tumour suppressor gene. Yet, to date, only one study has successfully utilised p53 status for patient stratification leading to patient benefit (Pettitt et al, 2012). What is going wrong? How come the most studied gene in human cancer has yielded so little clinical utility? This Special Issue of Cancers will explore some of the existing and future challenges as well as exciting new opportunities that have been revealed by recent research.
References
Pettitt, A.R.; Jackson, R.; Carruthers, S.; Dodd, J.; Dodd, S.; Oates, M.; Johnson, G.G.; Schuh, A.; Matutes, E.; Dearden, C.E.; et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the national cancer research institute CLL206 trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2012, 30, 1647–1655.
Prof. Mark Boyd
Dr. Nikolina Vlatković
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- p53
- MDM2
- tumour suppressor
- targeted therapy
- stratification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
